来源：新浪证券-红岸工作室 1月13日，采纳股份跌0.62%，成交额1.20亿元，换手率5.46%，总市值35.49亿元。 异动分析 辅助生殖+医疗器械概念+人民币贬值受益 1、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 2、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 该股筹码平均交易成本为27.99元，近期该股获筹码青睐，且集中度渐增；目前股价靠近压力位29.73， 谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。 公司简介 资料显示，采纳科技股份有限公司位于江苏省江阴市华士镇澄鹿路253号，成立日期2004年7月23日，上 市日期2022年1月26日，公司主营业务涉及医用和兽用注射穿刺器械及实验室耗材的研发、生产和销 售。主营业务收入构成为：注射器45.17%，穿刺针45.01%，实验室耗材5.49%，其他4.33%。 采纳股份所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：医疗器械、融资融券 ...

1月12日，品渥食品盘中上涨2.05%，截至10:57，报32.35元/股，成交6607.69万元，换手率3.20%，总市 值32.35亿元。 品渥食品所属申万行业为：食品饮料-饮料乳品-乳品。所属概念板块包括：国产乳业、多胎概念、新零 售、社区团购、电子商务等。 截至9月30日，品渥食品股东户数1.36万，较上期减少10.59%；人均流通股4739股，较上期增加 11.85%。2025年1月-9月，品渥食品实现营业收入5.89亿元，同比减少7.69%；归母净利润1215.33万元， 同比增长312.18%。 分红方面，品渥食品A股上市后累计派现5590.04万元。近三年，累计派现990.04万元。 责任编辑：小浪快报 资金流向方面，主力资金净流入352.95万元，特大单买入0.00元，占比0.00%，卖出133.63万元，占比 2.02%；大单买入1210.35万元，占比18.32%，卖出723.76万元，占比10.95%。 品渥食品今年以来股价涨6.52%，近5个交易日涨4.93%，近20日涨1.13%，近60日跌7.23%。 资料显示，品渥食品股份有限公司位于上海市普陀区长寿路652号10号楼308室， ...

1月8日，麦趣尔盘中上涨2.03%，截至13:53，报8.54元/股，成交5089.87万元，换手率3.73%，总市值 14.87亿元。 资金流向方面，主力资金净流出398.92万元，特大单买入0.00元，占比0.00%，卖出107.30万元，占比 2.11%；大单买入356.67万元，占比7.01%，卖出648.29万元，占比12.74%。 麦趣尔今年以来股价涨0.00%，近5个交易日跌0.35%，近20日跌11.32%，近60日跌11.50%。 资料显示，麦趣尔集团股份有限公司位于新疆昌吉州昌吉市麦趣尔大道，成立日期2002年12月30日，上 市日期2014年1月28日，公司主营业务涉及乳制品的生产和销售,烘焙食品的连锁经营。主营业务收入构 成为：烘焙食品52.59%，乳制品30.31%，其他12.68%，节日食品4.42%。 麦趣尔所属申万行业为：食品饮料-休闲食品-烘焙食品。所属概念板块包括：国产乳业、微盘股、多胎 概念、新零售、小盘等。 截至12月19日，麦趣尔股东户数2.05万，较上期增加3.96%；人均流通股7912股，较上期减少3.81%。 2025年1月-9月，麦趣尔实现营业收入4.63亿元 ...

Core Viewpoint - The stock price of Aihuilong has shown a significant increase in recent trading sessions, reflecting positive market sentiment despite a decline in revenue and net profit for the year [2][3]. Group 1: Stock Performance - Aihuilong's stock price increased by 11.69% since the beginning of the year, with a 11.85% rise over the last five trading days, 11.30% over the last 20 days, and 9.23% over the last 60 days [2]. - As of January 8, the stock was trading at 15.86 CNY per share, with a market capitalization of 9.062 billion CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Aihuilong reported a revenue of 1.287 billion CNY, a year-on-year decrease of 7.69%, and a net profit attributable to shareholders of 60.42 million CNY, down 72.36% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 693 million CNY, with 531 million CNY distributed over the last three years [3]. Group 3: Business Overview - Aihuilong, established on September 17, 2008, specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescent immunoassay technology [2]. - The company's revenue composition includes 58.57% from self-produced reagents (non-COVID products), 12.60% from self-produced consumables (non-COVID products), and 11.92% from self-produced instruments (non-COVID products) [2]. Group 4: Shareholder Information - As of September 30, 2025, Aihuilong had 12,800 shareholders, an increase of 7.40% from the previous period, with an average of 44,595 circulating shares per shareholder, a decrease of 6.89% [2]. - The seventh largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 9.6516 million shares, which is a decrease of 1.7669 million shares compared to the previous period [3].

1月8日，迪安诊断盘中上涨2.04%，截至09:54，报17.49元/股，成交9771.20万元，换手率1.13%，总市 值109.31亿元。 资金流向方面，主力资金净流出130.59万元，特大单买入104.21万元，占比1.07%，卖出463.49万元，占 比4.74%；大单买入2044.16万元，占比20.92%，卖出1815.46万元，占比18.58%。 分红方面，迪安诊断A股上市后累计派现10.99亿元。近三年，累计派现7.12亿元。 机构持仓方面，截止2025年9月30日，迪安诊断十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1056.35万股，相比上期减少423.50万股。南方中证1000ETF（512100）位居第七大流通股 东，持股456.88万股，相比上期减少4.09万股。医疗器械ETF（159883）位居第十大流通股东，持股 308.75万股，为新进股东。招商优势企业混合A（217021）、长城消费增值混合A（200006）退出十大 流通股东之列。 责任编辑：小浪快报 资料显示，迪安诊断技术集团股份有限公司位于浙江省杭州市西湖区金蓬街329号2幢5层，成立日期 2001年9 ...

截至9月30日，博汇纸业股东户数4.58万，较上期减少6.94%；人均流通股29216股，较上期增加7.46%。 2025年1月-9月，博汇纸业实现营业收入144.50亿元，同比增长3.46%；归母净利润1.21亿元，同比减少 18.57%。 分红方面，博汇纸业A股上市后累计派现8.89亿元。近三年，累计派现9435.66万元。 机构持仓方面，截止2025年9月30日，博汇纸业十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股864.47万股，相比上期增加31.02万股。南方中证1000ETF（512100）位居第九大流通股 东，持股732.93万股，相比上期减少8.68万股。华夏中证1000ETF（159845）退出十大流通股东之列。 1月8日，博汇纸业盘中下跌2.07%，截至10:05，报6.62元/股，成交4122.09万元，换手率0.46%，总市值 88.50亿元。 资金流向方面，主力资金净流出796.07万元，特大单买入0.00元，占比0.00%，卖出643.39万元，占比 15.61%；大单买入613.72万元，占比14.89%，卖出766.40万元，占比18.59%。 博汇纸业今年以 ...

Group 1 - The core viewpoint of the news is that Jinma Amusement's stock has experienced a decline in price, with a drop of 1.71% year-to-date and a 5.80% decrease over the last five trading days [2] - As of January 7, the stock price was reported at 55.91 yuan per share, with a market capitalization of 8.81 billion yuan [1] - The company has a diverse revenue structure, with amusement facilities accounting for 71.82% of total revenue, followed by parts and maintenance at 13.55%, ticket sales at 11.25%, and other income sources [2] Group 2 - For the period from January to September 2025, Jinma Amusement achieved a revenue of 569 million yuan, representing a year-on-year growth of 23.76%, while the net profit attributable to shareholders was 90.41 million yuan, up 456.47% [2] - The company has distributed a total of 83.50 million yuan in dividends since its A-share listing, with 23.64 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 13.99% to 7,324, while the average circulating shares per person decreased by 12.27% to 17,917 shares [2]

1月5日，读客文化盘中上涨2.15%，截至13:07，报9.98元/股，成交6936.10万元，换手率2.56%，总市值 39.95亿元。 资金流向方面，主力资金净流出473.00万元，特大单买入0.00元，占比0.00%，卖出231.03万元，占比 3.33%；大单买入1016.74万元，占比14.66%，卖出1258.71万元，占比18.15%。 读客文化今年以来股价涨2.15%，近5个交易日涨3.74%，近20日跌5.22%，近60日涨0.30%。 资料显示，读客文化股份有限公司位于上海市闵行区申长路1588号16号，成立日期2009年5月27日，上 市日期2021年7月19日，公司主营业务涉及图书的策划与发行及相关文化增值服务。公司主要产品或服 务包括纸质图书业务、数字内容业务、版权运营业务和新媒体运营业务。主营业务收入构成为：纸质图 书82.16%，数字内容17.69%，版权运营0.10%，推广服务等0.05%。 读客文化所属申万行业为：传媒-出版-大众出版。所属概念板块包括：字节跳动概念、知识产权、知识 付费、IP概念（谷子经济）、多胎概念等。 截至9月30日，读客文化股东户数1.54万，较上期减 ...

Group 1 - The core viewpoint of the news is that Weixin Kang's stock price has shown a slight increase of 2.09% this year, but has experienced declines over the past five, twenty, and sixty trading days [2] - As of January 5, Weixin Kang's stock price reached 10.74 yuan per share, with a total market capitalization of 4.674 billion yuan [1] - The company has seen a net inflow of main funds amounting to 46.92 thousand yuan, with large single purchases accounting for 13.15% of total transactions [1] Group 2 - Weixin Kang's main business involves the research, production, and sales of chemical drug formulations and their raw materials, with a revenue composition of 72.08% from market services and 27.92% from pharmaceuticals [2] - As of September 30, the number of Weixin Kang's shareholders increased by 14.14% to 16,500, while the average circulating shares per person decreased by 12.39% to 26,333 shares [2] - For the period from January to September 2025, Weixin Kang reported an operating income of 862 million yuan, a year-on-year decrease of 13.27%, and a net profit attributable to shareholders of 219 million yuan, down 9.90% year-on-year [2] Group 3 - Weixin Kang has distributed a total of 624 million yuan in dividends since its A-share listing, with 438 million yuan distributed over the past three years [3] - As of September 30, 2025, several institutions have exited the top ten circulating shareholders, including Guangfa Medical Health Stock A and Xinao Small and Medium Cap Mixed A [3]

Core Viewpoint - Jiuqi Co., Ltd. is experiencing a decline in stock price while maintaining a significant market presence in the bicycle and related products industry, with a focus on cross-border e-commerce and benefiting from the depreciation of the RMB [1][2]. Company Overview - Jiuqi Co., Ltd. was established on October 6, 2000, and went public on August 12, 2021. The company is based in Hangzhou, Zhejiang Province, and specializes in the design, research and development, production, and sales of bicycles and related components [6]. - The company's revenue composition includes: 32.36% from parts, 22.04% from other products, 17.86% from adult bicycles, 16.86% from children's bicycles, 10.42% from electric bicycles, and 0.32% from motorcycles [6]. Financial Performance - For the period from January to September 2025, Jiuqi Co., Ltd. achieved a revenue of 2.369 billion yuan, representing a year-on-year growth of 32.45%. The net profit attributable to the parent company was 129 million yuan, reflecting a year-on-year increase of 56.55% [6]. - The company has distributed a total of 493 million yuan in dividends since its A-share listing, with 291 million yuan distributed over the past three years [7]. Market Position and Product Offering - Jiuqi Co., Ltd. is one of the major exporters of bicycle products in China, offering a wide range of bicycles and related products across various sizes and series, catering to different age groups [2]. - The company has a strong presence in international markets, with 96.44% of its revenue coming from overseas, benefiting from the depreciation of the RMB [2]. Stock and Trading Analysis - As of December 31, the stock price of Jiuqi Co., Ltd. decreased by 0.13%, with a trading volume of 26.97 million yuan and a market capitalization of 3.68 billion yuan [1]. - The average trading cost of the stock is 17.56 yuan, and it is approaching a resistance level of 15.80 yuan, indicating potential for upward movement if this level is surpassed [5].